|
|
|||
|
||||
OverviewCancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma. Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment. Full Product DetailsAuthor: David B. Teplow (Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc ISBN: 9780443235344ISBN 10: 0443235341 Pages: 282 Publication Date: 01 November 2024 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Forthcoming Availability: Not yet available This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release. Table of Contents1. The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy Matt Giacalone 2. TBA Tiziana Vavalà 3. Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy Rio Sugimura and Logan Tang 4. Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance? Moein Ala, Fatemeh Afra, Seyed Parsa Eftekhar and Amir Salehi Farid 5. Rational Design of adjuvants boosts cancer vaccines Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki and Nobutaka Hanagata 6. Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma Khushwant S. Yadav 7. MAGNETIC NANOPARTICLES: AN EMERGING NANOMEDICINE FOR CANCER IMMUNOTHERAPY Phoomipat Jungcharoen, Jutatip Panaampon, Thanit Imemkamon and Charupong Saengboonmee 8. TBA Mi Liu 9. TBA Sarbajit Mukherjee 10. TBA Gerardo Cazzato III 11. Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment Eric JouReviewsAuthor InformationDavid B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid ß-protein (Alzheimer's disease) and a-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease. Tab Content 6Author Website:Countries AvailableAll regions |